Workshop Learning Objectives

By the end of the meeting, participants will: be able to discuss new concepts in rheumatic diseases; be able to appraise new treatment paradigms and guidelines for rheumatic diseases; be able to encourage peer mentoring. The meeting will allow for clinical and scholarly collaboration, and to interact with members of the Arthritis Health Professions Association for the benefit of our patients.

Wednesday, February 24, 2021

1A Rheumatoid Arthritis: T2T to D2T, that is the question! – Iain McInnes

This session will explore difficult to treat RA, treat to target tips, and new drugs in old practice.

At the end of this session, participants will be able to:

  1. describe the advantages in the application of Treat to Target strategies in clinical practice in the treatment of rheumatoid arthritis (RA)
  2. define the difficult to treat patient with RA
  3. understand recommended clinical management approaches to RA that comprise T2T principles but that recognize additional approaches that can address the rarer difficult to treat patient subgroup

CanMEDS roles 

  1. Medical Expert
  2. Scholar
  3. Professional
1B Diagnosis and treatment of Giant Cell Arteritis – Philip Seo

Giant cell arteritis is the most common of all the systemic vasculitides.  This session will review common scenarios and discuss best management strategies.

At the end of this session, participants will be able to:

  1. review different presentations of giant cell arteritis
  2. discuss diagnostic strategies for giant cell arteritis
  3. review new treatment strategies for GCA

CanMEDS roles

  1. Medical Expert
  2. Health Advocate
  3. Scholar
1C A Day in the Life of a Respirheumatologist – Deborah Assayag and Marie Hudson

This will be a case-based workshop focused on the practical aspects of diagnosis and management of interstitial lung disease in the setting of myositis, scleroderma and RA.

At the end of this session, participants will be able to:

  1. recognize different patterns of CTD-ILD
  2. discuss the role of the multi-disciplinary team meeting
  3. discuss the place of anti-fib

CanMEDS roles

  1. Medical Expert
  2. Collaborator
  3. Scholar
1D Growing a Grown-up Brain: Implications for Youth Transiting to Adult Care – Elizabeth Stringer, Alene Toulany, Nadia Luca

The transition from pediatric to adult care is a high-risk period with up to 50% of youth being lost to follow-up after transfer. This time-period coincides with many other important transitions occurring during normal adolescent development, which continues into early adulthood. To provide high quality care for this youth and young adults, pediatric and adult health care providers must understand how the normal stages of adolescent development can affect behaviors and decision-making in relation to self-management of a chronic condition. This interactive workshop will bring together patient perspectives and expertise in adolescent medicine to provide insight into the journey of becoming a young adult with rheumatic disease while transitioning to adult care.

At the end of this session, participants will be able to:

  1. define the key adolescent developmental milestones and appreciate how each stage may impact the health care behaviors and choices of transition-age youth
  2. understand the impact of a chronic childhood illness on the normal stages of adolescent development and how this may impact transfer and transition to adult care
  3. develop practical skills and insights around caring for and communicating with this highly engaging, and sometimes challenging, population

CanMEDS roles

  1. Communicator
  2. Collaborator
  3. Leader
  4. Health Advocate
  5. Professional
1E Transition from Pediatrics to Adult Care: What Does the Adult Rheumatologist Need to Know? – Natasha Gakhal, Evelyn Rozenblyum, Danielle McCormack

JIA patients transitioning from pediatric care requires a unique and tailored approach to care where these young adults with chronic disease are in a unique developmental period where patients require education and guidance to develop into independent adults managing their own health.  JIA also has unique medical concerns that require expertise and knowledge to manage. This session will provide clinical pearls and practical tips in treated young adults with JIA.

At the end of this session, participants will be able to:

  1. identify specific monitoring required for patients with JIA
  2. deconstruct nuisances of TMJ disease- diagnosis and treatment strategies
  3. address the social and vocational issues specific to patients with JIA

CanMEDS roles

  1. Medical Expert
  2. Collaborator
  3. Scholar
1F Complex Cases in Osteoporosis – Laetitia Michou

This interactive workshop will focus on complex cases in osteoporosis, through clinical cases and highlighting the importance of interdisciplinary collaboration in the management of osteoporosis.

At the end of this session, participants will be able to:

  1. identify very high risk of osteoporotic fractures
  2. recognize the main contraindications to bone forming agents
  3. manage an osteoporotic patient with a treatment failure

CanMEDS roles

  1. Medical Expert
  2. Communicator
  3. Health Advocate
1G Management of Systemic Sclerosis – Janet Pope

This workshop will be case based and allow for interaction.  It will describe evidence and eminence-based treatment of scleroderma complications. There will be audience polling and a question period. There will be a section for choose your own adventure where the audience can determine which SSc complication is of most interest to them.

At the end of this session, participants will be able to:

  1. To be informed of recent RCT evidence for the treatment of SSc complications including ILD and PAH.
  2. To consider appropriate treatment for RP and GI complications in SSc.
  3. To be aware of the prognosis of SSc in the patients you follow.

CanMEDS roles 

  1. Medical Expert
  2. Collaborator
  3. Leader
  4. Health Advocate
  5. Scholar
1H Reproduction and Rheumatic Disease – Carl Laskin and Dharini Mahendira

This interactive, case-based workshop shall aim to: (1) review considerations for risk stratification and pre-natal planning in women with SLE, APLAS, RA and spondyloarthropathies; (2) discuss anticipated rheumatic disease course during pregnancy; (3) provide an update on the safety of anti-rheumatic drugs during pregnancy as well as to (4) discuss fertility considerations in women with rheumatic diseases.

At the end of this session, participants will be able to:

  1. describe risk stratification and pregnancy planning in women with rheumatic diseases, such as SLE and RA
  2. identify the safety profile of newer anti-rheumatic therapies in the context of pregnancy and lactation
  3. demonstrate increased confidence with balancing maternal and fetal health considerations when managing fertility issues and pregnancy in women with rheumatic diseases

CanMEDS roles

  1. Medical Expert
  2. Leader
  3. Scholar
1I Novel Drugs in Lupus/Sjogren’s Syndrome – Zahi Touma

At the end of this session, participants will be able to:

  1. list newly approved drugs for lupus and promising new treatments
  2. identify the role of biologics in the treatment of lupus
  3. understand the use of new treatment modalities in renal and extra-renal manifestations

CanMEDS roles

  1. Medical Expert
  2. Health Advocate
  3. Scholar

Thursday, February 25, 2021

2A Horror Autoinflammaticus: The Expanding Universe of Autoinflammatory Disease – Dan Kastner

In this workshop we will review the clinical features, genetics, pathophysiology, and treatment of selected autoinflammatory diseases.

At the end of this session, participants will be able to:

  1. describe the major clinical features distinguishing the hereditary recurrent fevers
  2. interpret basic genetic test results for autoinflammatory disease
  3. discuss the role of biologics in the treatment of selected autoinflammatory diseases

CanMEDS roles

  1. Medical Expert
  2. Scholar
  3. Professional
2B Anti-phospholipid Antibody Syndrome – Leslie Skeith

A review of the latest evidence and controversies in antiphospholipid syndrome

At the end of this session, participants will be able to:

  1. describe the role of complement activation in APS
  2. review management of thrombotic APS
  3. review management of obstetric APS

CanMEDS roles

  1. Medical Expert
  2. Collaborator
  3. Professional
2C Inflammatory Skin Disease – Sheila Au, Jan Dutz and Stephanie Keeling

This session will review morphea and eosinophilia fasciitis, scleroderma type conditions and urticaria eruptions.

At the end of this session, participants will be able to:

  1. identify morphologies of scleroderma type skin diseases
  2. review the presentation and course of eosinophilic fasciitis
  3. develop an approach to urticaria eruptions

CanMEDS roles

  1. Medical Expert
  2. Health Advocate
  3. Scholar 
2D Neonatal Lupus Erythematosus – Linda Hiraki, Edgar Jaeggi, Evelyne Vinet

Neonatal Lupus Erythematosus: what every adult and pediatric rheumatologist should know

This workshop will present a comprehensive overview of Neonatal Lupus Erythematosus, including cardiology, and both adult and pediatric rheumatology perspectives.  It will explore the manifestations of Neonatal Lupus Erythematosus, NLE screening and following children born to Anti-Ro positive mothers. Evidence for the role of maternal hydroxychloroquine use will be presented as well as long-term outcomes for children with NLE and babies with complete AVB.  Current protocols for pregnancy management of women with SLE will be discussed in addition to the identification and treatment of pregnancies at risk of cardiac NLE. 

At the end of this session, participants will be able to:

  1. screen and identify the clinical manifestations of neonatal lupus erythematosus 
  2. counsel families on the role of maternal hydroxychloroquine use and neonatal lupus erythematosus
  3. discuss current recommendations for pregnancy management of women with SLE
  4. describe the evidence-based data on antimalarial use for prevention of NLE
  5. review the risk of immune-mediated fetal heart disease, who should be offered prenatal screening during the pregnancy, the immune-mediated heart conditions and their prognosis and management

CanMEDS roles

  1. Medical Expert
  2. Communicator
  3. Collaborator
  4. Health Advocate
2E Are you kidding me Corona? Having Arthritis is hard enough! A Pandemic’s Impact on the Mental Health of Clients with Rheumatic Disease – Anna Nikitina

Adapting to Arthritis with a positive outcome involves learning new coping strategies. COVID-19’s impact caused those strategies to be taken away and resulted in one of the greatest increases of mental health diagnoses we have ever seen. Join us for the details. 

At the end of this session, participants will be able to:

  1. recognize how a client’s arthritis affects their mental health 
  2. understand coping strategies clients use to adapt positively to their condition
  3. recognize how the impact of COVID-19 took away these coping strategies and negatively impacted their mental health

CanMEDS roles

  1. Communicator
  2. Collaborator
2F COVID-19 in rheumatic disease: can we recover and what can we uncover? – Arielle Mendel, Lihi Eder, Hugues Allard-Chamard, Rae Yeung, Paul Fortin and Ines Colmegna

In this workshop, CAnadian Network for REsearch on COVID-19 and Rheumatology (CAN-RECOVR) investigators will discuss diverse avenues of “COVID-ology” in rheumatology and together we will prioritize future research questions.

At the end of this session, participants will be able to:

  1. describe questions (and early answers) generated on the topic of COVID-19 and rheumatic disease
  2. identify Canadian researchers’ approaches to the study of COVID-19 in rheumatic diseases
  3. discuss collective priorities for research and innovation in COVID-19 and rheumatology

CanMEDS roles

  1. Communicator
2G Rheumatic Complications of Cancer Immunotherapy:  The Knowns and the Unknowns – Janet Roberts

 This session will review the evolving literature on the topic of rheumatic complications of immunotherapy and the integral role of the rheumatologist in the co-management of these patients.  It will include a discussion of the most common rheumatic complications rheumatologists may be faced with and important considerations for our patients with pre-existing rheumatic disease being treated with these agents.  

At the end of this session, participants will be able to:

  1. identify the most common rheumatic complications of immunotherapy and the appropriate management based on severity
  2. understand the most recent evidence to guide management of pre-existing rheumatic disease prior to, during and following cancer immunotherapy
  3. describe the role of the rheumatologist in the management of cancer patients treated with immunotherapy

CanMEDS roles

  1. Medical Expert
  2. Leader
  3. Scholar
2H Therapeutic Drug Monitoring of Biologic Agents in Rheumatology – Ruud Verstegen

This workshop will focus on the current applications and future perspectives of therapeutic drug monitoring of biologic agents in rheumatology.

At the end of this session, participants will be able to:

  1. understand current practical applications of therapeutic drug monitoring in the management of rheumatic conditions
  2. understand the real-world challenges of therapeutic drug monitoring in Rheumatology
  3. recognize potential future applications of therapeutic drug monitoring in Rheumatology

CanMEDS roles

  1. Collaborator
2I How Do I Fill Out that Disability Form? – Beth Hazel, Christiane Azar, Roger Talbot

Rheumatologists are often asked to fill out disability forms.  This session will address some of the medico-legal and ethical issues related to this issue.

At the end of this session, participants will be able to:

  1. recognize the importance of having an objective approach
  2. list two prerequisites for providing forms and reports
  3. give examples of problems that may arise from failure to recognize any limitations to your information or knowledge

CanMEDS roles

  1. Medical Expert
  2. Collaborator
  3. Health Advocate

Friday, February 26, 2021

3A Vaccination and Infection in the Rheumatic Patient – Michael Libman

This session presents a pragmatic approach to assessing a patient likely to start on immunomodulatory treatment.

At the end of this session, participants will be able to:

  1. explain common infections which could be prevented or mitigated by vaccination
  2. identify chronic infections which may be reactivated by immunomodulatory agents
  3. discuss the optimal timing of vaccines or preventive treatments

CanMEDS roles 

  1. Medical Expert
  2. Scholar
3B An Unprecedented Year in Lupus Drug Development: An Update for CliniciansJinoos Yazdany

2020 has been an unprecedented year for lupus drug development. In this talk, we will review key clinical trials and discuss how these trials will influence practice through case-based discussions.

At the end of this session, participants will be able to:

  1. describe the key findings from landmark clinical trials in SLE performed in the last year
  2. identify clinical scenarios where trial findings might be applied in clinical practice
  3. discuss challenging SLE cases

CanMEDS roles

  1. Medical Expert
  2. Communicator
  3. Scholar
3C Muscle Weakness/Myositis – Helene Alexanderson and Brian Feldman

In this session we will discuss the principles underlying exercise in rehabilitation (including supplementation) in myositis – both for adults and children.

At the end of this session, participants will be able to:

  1. describe why muscles become weak in the idiopathic inflammatory myopathies, and understand the role of energetics and supplementation in the muscle of these patients
  2. understand the role of exercise and rehabilitation in the idiopathic inflammatory myopathies
  3. recognize the consensus clinical outcome measures to assess muscle impairment in adult and childhood myositis

CanMEDS roles

  1. Medical Expert
  2. Scholar
3D Multisystem Inflammatory Syndrome in children (MIS-C/PIMS): The CHU Sainte-Justine experience- Marie-Paule Morin and Elie Haddad

This session will present a discussion around the evolving literature around clinical presentation and treatment of children presenting with suspected MIS-C/PIMS.

At the end of this session, participants will be able to:

  1. identify the different criteria for PIMS/MIS-C diagnosis
  2. distinguish PIMS-MIS-C from classical Kawasaki disease
  3. apply current guidelines in the treatment of PIMS-MIS-C children

CanMEDS roles 

  1. Medical Expert
  2. Collaborator
  3. Scholar
3E Steering Your Clients Through the Weight Loss Jungle! – Kim Arrey, Vincent Bernatchez

In this lively session, a registered dietitian and a kinesiologist will guide you through the weight loss jungle, separating myth from fact and offering some options for your patients. By the end of this session, you will be able to guide your clients to the right program for them and help them along the trail to a healthier weight.

At the end of this session, participants will be able to:

  1. choose appropriate referral options for weight management programs
  2. develop appropriate dietary, exercise, and weight management goals with clients
  3. describe the impact of both diet and exercise on weight management

CanMEDS roles

  1. Medical Expert
  2. Collaborator
  3. Scholar
3F COVID-19 Fact, Fiction, and the Future – Zain Chagla

A review of the world of COVID-19, starting with current therapeutic options and level of evidence, followed by some of the misinformation and lessons learned, and finally the vaccine future.

At the end of this session, participants will be able to:

  1. identify the current therapeutic targets for COVID-19 and the evidence
  2. recognize misinformation in the pandemic
  3. review vaccinations and the road ahead

CanMEDS roles

  1. Medical Expert
  2. Scholar
3G Non-radiographic Axial Spondyloarthritis:  Diagnosis and Management – Jonathan Chan

This session will discuss classification and controversies, address how to make a confident diagnosis, and provide an update on treatment and management.

At the end of this session, participants will be able to:

  1. discuss classification and controversies
  2. address how to make a confident diagnosis
  3. understand an update on treatment and management

CanMEDS roles

  1. Medical Expert
  2. Communicator
  3. Scholar
3H EGPA, GPA, MPA or NPA? That is the question! – Jan Willem Cohen Tervaert, Elaine Yacyshyn, Mo Osman, Alison Clifford

In this interactive workshop, the focus will be on making a diagnosis of ANCA-associated vasculitis. Furthermore, new developments in the treatment of the different forms of vasculitis and outcome research will be discussed.

At the end of this session, participants will be able to:

  1. identify and diagnose vasculitis
  2. apply treatment for vasculitis
  3. recognize outcomes of vasculitis

CanMEDS roles

  1. Medical Expert
  2. Communicator
  3. Health Advocate
  4. Scholar
3I What Can SR&ED Credits Do for You and Your Practice? – Janet Pope, Carter Thorne

There is an opportunity to incorporate clinical research in your practice and claim Scientific Research and Development Tax Credits which could provide a substantial refund and pay for your involvement in so many Canadian registries. This workshop will tell you about SR&ED credits.

At the end of this session, participants will be able to:

  1. describe the SR&ED program
  2. discuss the incorporation of research into normal practice.
  3. identify practice consideration procedures needed for SR&ED credits

CanMEDS roles

  1. Collaborator
  2. Leader
  3. Professional